Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients

PURPOSE: ERBB2 exon 20 insertions (20ins) have been identified as oncogenic drivers in lung cancers. Lung cancer patients with 20ins benefit from afatinib. However, response heterogeneity was observed in patients harboring different 20ins subtypes. In this study, we interrogated clinical characteris...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Liu, Zhefeng, Wu, Lin, Cao, Jun, Yang, Zhe, Zhou, Chengzhi, Cao, Liming, Wu, Hao, Shen, Haibo, Jin, Meiling, Zhang, Yong, Mao, Xinru, Xiang, Jianxing, Ma, Ke, Li, Bing, Zhang, Tengfei, Hu, Yi
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6205822/
https://ncbi.nlm.nih.gov/pubmed/30425522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S173391
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars